Compare Norfolk Southern Corporation (NSC) vs Pfizer Inc (PFE) Price & Performance

Norfolk Southern (NSC) trades at $327.92, down 0.47% on the day, amid a bearish technical signal. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Key fundamentals show strong profitability with a 21.02% net income margin and 16.97% ROE, though valuation multiples like the P/E of 27.98 appear elevated. Recent news highlights ongoing institutional accumulation and progress in the proposed merger with Union Pacific, which remains under regulatory review.

The outlook is balanced; the merger potential offers upside, but regulatory hurdles and a premium valuation pose risks. Analyst consensus is mixed with a Hold rating predominating, though the $369.67 price target implies modest upside. Earnings sustainability and merger approval are critical for near-term direction.

Pfizer (PFE) trades at $27.78, down 2.36% today, with a consensus price target of $28.33 suggesting modest upside. The stock shows mixed technical signals with bullish moving averages but neutral oscillators. Recent earnings have consistently beaten expectations, though revenue declined from pandemic peaks. The company maintains strong cash flow generation and a solid dividend yield of approximately 3.1%.

Pfizer presents a value opportunity with reasonable valuation metrics and dividend stability, but faces headwinds from post-COVID revenue normalization and patent expirations. The company's pipeline progress in obesity and oncology could drive future growth, though execution risks remain. Analyst sentiment leans cautious with 59% hold ratings.